Enter search term

ZEUS Borrelia MTTT™ improves Lyme patient outcomes during the summer of COVID-19

Aug 6, 2020

ZEUS Borrelia MTTT™ Improves Lyme Patient Outcomesduring the Summer of COVID-19

After months of shutdowns, mandatory quarantines, self-imposed exile from society and working from home, nature-lovers looking for a well-earned breath of fresh air face a collision course between coronavirus and Lyme disease this summer.  A "perfect storm," warns Eva Sapi, a University of New Haven biology professor and group director for the Lyme Disease Research Group.  Noting the mild winter on the East Coast, Sapi says, "We do have a bad year for the ticks."  As with coronavirus, the number of reported Lyme disease cases is likely undercounted. While the CDC estimates 30,000 Americans contract Lyme yearly, the federal agency notes recent estimates suggest that the true number may be 10 times higher, around 300,000.

Last month, Pennsylvania Secretary of Health Dr. Rachel Levine announced an increase in emergency room visits over the past several months "related" to tick bites. "Some symptoms of Lyme disease, such as fever, chills and headache, are similar to symptoms of COVID-19," Dr. Levine said in a statement, reiterating what other experts say.  As the COVID-19 pandemic continues through the summer into fall, the ability to accurately diagnose Lyme disease remains critical.  Delaying treatment for Lyme disease can be dangerous to your health. When Lyme disease is diagnosed and treated in its early stages, most patients experience a full recovery.  But if the disease is not caught early, it can lead to serious medical complications, including heart conditions, joint swelling, extreme fatigue, neuropsychiatric symptoms such as trouble with mood control and sensory processing, and cognitive deficits such as impaired fine motor control and poor memory.



ZEUS Borrelia MTTT™ is a simpler, more cost effective, faster and better way to more accurately detect Lyme disease than using immunoblots. This updated algorithm detected up to 30% more positive patients in acute early Lyme disease, the critical time to correctly identify and treat! 

If you are sending out your confirmatory tests instead of running them in house, you no longer have to!  ZEUS Borrelia MTTT™ makes it easier for all labs to quickly turn around both steps of the Lyme disease testing algorithm.

If you are still running Lyme disease immunoblots in your laboratory, take a look at the clinical data to see how ZEUS Borrelia MTTT™ improves detection in early Lyme disease.

If you need more information please visit zeuslyme.com or contact your local account manager.

With the only FDA-approved Modified Two-Tiered Testing algorithm available, let us help you improve your ability to provide your physicians the right answers their patients sorely need!



The ZEUS Scientific Team

Back Share